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We noted a marked diminution of absolute B cell numbers, as Silverman also found. '9 Before infusion the mean absolute B cell number was 7584i1 (320-1200) and after six hours 238/4d (65-494). This is clinically important as it temporarily interrupts antibody production. The immunomodulation caused by the megadose intravenous steroid dose was only transitory and the T subpopulation and B cell level returned to their initial levels 24 hours after the infusions. Because methylprednisolone is rapidly excreted (half life: three hours) 99% of the dose is eliminated in one day, and thus its effect diminishes rapidly. 8 Several authors have noted a significant decrease in the IgG, IgA, C3, C4, and immune complex concentrations after methylprednisolone pulse therapy.5 20 21 These indices of humoral immune response were normal in our patients: (IgG 12-5 (SD 3-633) -11i6 (2-986) g/l; IgA [2] [3] (1-4)-2-2 (1-1) g/l; IgM 1-09 (0-48)-l-17 (0-32) g/l; C3 0-93 (0-12)-1.09 (023) g/l; C4 0-27 (0-13)-0-24 (0-1) g/l) and were unchanged during the methylprednisolone pulse therapy.
The immune complex concentration was normal before the infusion: mean 210-6 ng/ml (124-303), and use in helping us to decide whether to continue with or to change treatment. In a clisical trial the scores can be readily used to define entry criteria, to describe the patient sample, and to describe the response to treatment.
Another dimension of response is time. If the same degree of improvement is achieved over six months with one drug and over one year with another, then clearly the former is more desirable. Any statement about response must include the time span. Scott et al suggest that six months is an appropriate time to assess response to second line agents on the grounds that if a patient is to show a favourable response they will have done so by this time.
As the longer term effect of these drugs is still open to debate this seems to be a reasonable suggestion, though careful data analysis indicates that most of the improvement in 'responders' has occurred by 18 weeks. 3 The consensus meeting' was right to identify the need for a simple response index, but such an index must be independently validated and acceptable to most rheumatologists. This is particularly important in view of the extensive disagreement between clinicians in judging rheumatoid arthritis disease progress. 5 This patient has shown a clear response to a drug, albeit partial, but the use of the suggested response criteria would fail to show this, so the treatment would be deemed ineffective. In this situation the addition of a second drug rather than a change of treatment may produce further improvement. Sir: Dr Dixon and Dr Davis and his colleagues raise several relevant points in their letters, and it is encouraging that our article has stimulated such interesting comments. As some oftheir points are similar it is appropriate to provide a single response.
How should variables used to define the response to slow acting antirheumatic drugs be selected? There is no easy answer and although we developed one approach, other methods can be used. Dixon and his colleagues adopted a slightly different method to ours,' and, similarly, the index of Davis and his colleagues, is also slightly different in its construction and includes measurement of C reactive protein.2 Despite this my colleagues and I feel intuitively that a simple measure which is widely used and shows considerable change is better than one which shows little change, and this view underlies our approach.
A second area of debate is whether to use fixed points (such as an erythrocyte sedimentation rate of 30 mm/h) to define response or to have more sensitive measures relecting change. The limitation of fixed points was shown in the theoretical example given by Dixon. It was also hinted at by Davis et al where they suggest minor degrees of improvement may be shown by a more sensitive index which would allow them to use combination treatment with two slow acting antirheumatic drugs. Our intention was to provide the simplest possible index which gave acceptable results, and we found this approach was effective in practice. Inevitably, such a reductionist method will have limitations, but we suggest these are theoretical rather than practical. There is a need for comparative analyses of different approaches.
It is unlikely that our simple index will be the only measure of response used in rheumatoid arthritis. It figure) . Rectification and syndesmophytes were found after radiographic examination of the lumbar spine. A technetium-99m bone scan showed uptake in the left sacroiliac joint. Another arthrocentesis of the elbow was carried out, but bacterial and mycobacterial cultures proved negative. After an infiltration of intra-articular corticosteroids the patient greatly improved for one month, and three months later a rhenium chemical synovectomy was carried out. Five months later he continued to be free from pain in the elbow (extension 50°, flexion 1200).
In this case the temporal relation between both physical injuries and the development of peripheral arthritis is striking. There is little doubt about the diagnosis of seronegative spondyloarthropathy in this patient. He had clinical and radiological evidence of lesions in the lumbar spine and the left sacroiliac joint. He developed rapid joint destruction in the left elbow and left knee after both physical injuries.
Our patient, unlike previous cases' -4 of peripheral arthritis precipitated by trauma, did not have the HLA-B27 antigen, but was B7 positive. We think this is the first case of spondyloarthropathy related to trauma in a B27 cross-reactive antigen (CREG group). At least 12 well described cases of spondyloarthropathy triggered by trauma have been reported in recent years. Some presented as Reiter's syndrome,3 ' 8 others as peripheral arthropathy,' 2 4 and all of them were B27 positive. Seronegative spondarthritides include a heterogeneous group of disorders occurring in genetically predisposed subjects after exposure to environmental triggers.9 10 We agree with those who suggest that physical injury may precipitate this arthropathy. ' Genetic predisposition is clearly marked by HLA-B27, and perhaps by other antigens of the cross-reactive group (CREG), but to establish this fact more studies are necessary. 
